Cargando…

A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma

BACKGROUND: Patients with recurrent/metastatic uterine leiomyosarcoma (U-LMS) have a dismal prognosis. This phase II study aims to evaluate trabectedin efficacy and safety in advanced U-LMS. METHODS: Eligible patients had received ≥ one line of chemotherapy. Gemcitabine ± docetaxel naive patients we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gadducci, Angiolo, Grosso, Federica, Scambia, Giovanni, Raspagliesi, Francesco, Colombo, Nicoletta, Grignani, Giovanni, Casali, Paolo, Sanfilippo, Roberta, Buonadonna, Angela, Santoro, Armando, Bruzzone, Milena, Artioli, Grazia, Lorusso, Domenica, Biagioli, Elena, Fossati, Roldano, Galli, Francesca, Negri, Emanuele, Rulli, Eliana, Torri, Valter, D’Incalci, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162262/ https://www.ncbi.nlm.nih.gov/pubmed/30057406 http://dx.doi.org/10.1038/s41416-018-0190-y

Ejemplares similares

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
por: Colombo, Nicoletta, et al.
Publicado: (2019)

Management Strategies in Advanced Uterine Leiomyosarcoma: Focus on Trabectedin
por: Amant, Frédéric, et al.
Publicado: (2015)

Assessment of proportional hazard assumption in aggregate data: a systematic review on statistical methodology in clinical trials using time-to-event endpoint
por: Rulli, Eliana, et al.
Publicado: (2018)

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma
por: Gadducci, Angiolo, et al.
Publicado: (2022)

New activities for the anti-tumor agent trabectedin: taking two birds with one stone
por: D'Incalci, Maurizio, et al.
Publicado: (2013)

Trabectedin: A drug from the sea that strikes tumor-associated macrophages
por: Allavena, Paola, et al.
Publicado: (2013)

Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2019)

Trabectedin and Plitidepsin: Drugs from the Sea that Strike the Tumor Microenvironment
por: Galmarini, Carlos M., et al.
Publicado: (2014)

Correction: Establishment and characterisation of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin
por: Bello, Ezia, et al.
Publicado: (2020)

Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
por: D'Incalci, M, et al.
Publicado: (2014)

Editorial: Trabectedin, lurbinectedin, and other marine-derived anticancer alkaloids on solid cancer: Mechanisms of action, clinical impact, and future perspectives
por: Zambelli, Alberto, et al.
Publicado: (2023)

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment
por: Allavena, Paola, et al.
Publicado: (2022)

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB
por: Camorani, Simona, et al.
Publicado: (2018)

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms
por: Romano, Michela, et al.
Publicado: (2017)

Mechanism of action of trabectedin in desmoplastic small round cell tumor cells
por: Uboldi, S., et al.
Publicado: (2017)

Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin
por: Fabbroni, Chiara, et al.
Publicado: (2021)

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma
por: De Sanctis, Rita, et al.
Publicado: (2015)

Inhibition of tumor‐associated macrophages by trabectedin improves the antitumor adaptive immunity in response to anti‐PD‐1 therapy
por: Belgiovine, Cristina, et al.
Publicado: (2021)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

A systems biology approach to investigate the mechanism of action of trabectedin in a model of myelomonocytic leukemia
por: Mannarino, L, et al.
Publicado: (2018)

Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma [Corrigendum]
Publicado: (2016)

Long-lasting activity of trabectedin in refractory uterine leiomyosarcoma: a case report
por: Bongiovanni, Alberto, et al.
Publicado: (2015)

Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers
por: Fucà, Giovanni, et al.
Publicado: (2020)

A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
por: Grosso, Federica, et al.
Publicado: (2012)

Transcription regulators and ultra-rare and other rare translocation-related sarcomas treated with trabectedin: A proof of principle from a post-hoc analysis
por: Palmerini, Emanuela, et al.
Publicado: (2022)

Case Report of Suspected Rhabdomyolysis during Treatment with Trabectedin in a Patient with Metastatic Leiomyosarcoma
por: Lamm, W., et al.
Publicado: (2010)

Pharmacometabolomics of trabectedin in metastatic soft tissue sarcoma patients
por: Corona, Giuseppe, et al.
Publicado: (2023)

Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis
por: Ciccarone, Francesca, et al.
Publicado: (2022)

Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group
por: Palmerini, Emanuela, et al.
Publicado: (2021)

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity
por: Herzog, J., et al.
Publicado: (2016)

A Systems Biology Approach to Characterize the Regulatory Networks Leading to Trabectedin Resistance in an In Vitro Model of Myxoid Liposarcoma
por: Uboldi, Sarah, et al.
Publicado: (2012)

Long-Lasting Response to Trabectedin in a Patient with Metastatic Uterine Leiomyosarcoma: A Case Report
por: Nteli, Viktoria-Anna, et al.
Publicado: (2018)

Long lasting response of trabectedin in patient with gastric leiomyosarcoma with liver metastasis: an update to previous report
por: Rastogi, Sameer, et al.
Publicado: (2019)

Trabectedin and Radiation Therapy for Cardiac Metastasis From Leiomyosarcoma: A Case Report and Review of the Literature
por: Tortorelli, Ilaria, et al.
Publicado: (2022)

Pharmacological Treatment of Patients with Metastatic, Recurrent or Persistent Cervical Cancer Not Amenable by Surgery or Radiotherapy: State of Art and Perspectives of Clinical Research
por: Gadducci, Angiolo, et al.
Publicado: (2020)

Therapeutic Approach to Low-Grade Serous Ovarian Carcinoma: State of Art and Perspectives of Clinical Research
por: Gadducci, Angiolo, et al.
Publicado: (2020)

Pharmacological Treatment of Advanced, Persistent or Metastatic Endometrial Cancer: State of the Art and Perspectives of Clinical Research for the Special Issue “Diagnosis and Management of Endometrial Cancer”
por: Gadducci, Angiolo, et al.
Publicado: (2021)

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
por: Mascilini, Floriana, et al.
Publicado: (2014)

Long-Term Progression-Free Survival in a Patient with Metastatic Leiomyosarcoma of the Inguinal Region Treated with Trabectedin
por: Haslbauer, Ferdinand
Publicado: (2018)

Long-Time Progression-Free Survival with Trabectedin in Chemorefractory Metastatic Leiomyosarcoma of the Retroperitoneum: A Case Report
por: Reichinger, Andreas
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gote4k05g5e52l0oq2o5r8029a